Imagine having a high-tech GPS for your arteries that doesn't just show where the blockage is, but tells you exactly what the blockage is made of. This project creates special 'smart' antibodies that act like beacons to light up dangerous plaques in medical scans. These same antibodies can then be used as precision medicine to flip a switch in the immune system, turning harmful cells into protective ones to clear the arteries.
Current cardiovascular diagnostics fail to accurately characterize plaque vulnerability, leading to missed opportunities for early intervention in patients at high risk of heart attack and stroke.
A library of human antibodies, 68Ga-labelled PET tracers, and bispecific antibodies for targeted immunotherapy.
If you are a radiopharmaceutical developer dealing with low-specificity cardiac scans — this project developed 68Ga-labelled PET tracers that allow for detailed plaque characterization. This enables the creation of high-resolution multi-marker PET/MRI protocols for better patient staging.
If you are an immunotherapy biotech dealing with the difficulty of targeting specific arterial inflammation — this project developed bispecific antibodies designed to reprogram harmful monocyte/macrophage populations. This provides a path toward targeted plaque regression therapy.
If you are a clinical biomarker lab dealing with the lack of early warning signs for heart attacks — this project identified human antibody molecular targets that can serve as soluble biomarkers for atherosclerosis. This allows for earlier intervention in high-risk patients.
Based on available project data, there is no information regarding the cost or pricing of the tracers.
The project involves 3 industrial partners and 2 SMEs, suggesting a focus on translational potential, but specific industrial scaling data is not provided.
Based on available project data, the specific IP and licensing terms are not disclosed, though the project involves a consortium of 8 partners across 3 countries.
The project period runs from 2024-04-01 to 2028-03-31, indicating that clinical translation activities are ongoing through 2028.
The system is designed to integrate with standard PET and MRI imaging systems to provide a combined multi-marker diagnostic tool.
The consortium is well-balanced for translational research, consisting of 8 partners from 3 countries (FR, ES, NL). With an industry ratio of 38% (including 3 industrial partners and 2 SMEs), there is a strong bridge between the 3 universities and 2 research institutes and the commercial market, ensuring that the antibody engineering and PET/MRI protocols are developed with industrial application in mind.
Contact the Universite de Bordeaux research office regarding the ABCardionostics project.
Contact SciTransfer for detailed partnership matchmaking with the ABCardionostics consortium.
